Charles River Laboratories International Inc.

NYSE:CRL  
226.32
+5.74 (+2.60%)
Other Pre-Announcement

Charles River Labs Now Sees High-Single-Digit Growth In Reported Revenue For Q2 2022 Vs. Q2 2021

Published: 06/08/2022 11:35 GMT
Charles River Laboratories International Inc. (CRL) - Now Sees High-single-digit Growth in Reported Revenue for Q2 Versus.
2q21.
Now Sees Low-double-digit Growth in Organic Revenue for Q2 Versus.
2q21.
Now Sees Low-to Mid-single-digit Growth in Non-GAAP EPS for Q2 Versus.
2q21.
Charles River Laboratories International - Expects FY 2022 Organic Revenue Growth and Non-GAAP EPS Will Remain Within Guidance Ranges Provided in May.
Q2 Earnings per Share View $2.82, Revenue View $1.01 Billion -- Refinitiv Ibes Data (analyst estimates).
FY2022 Earnings per Share View $11.62, Revenue View $4.04 Billion -- Refinitiv Ibes Data (analyst estimates).